{"filing":{"accession_number":"0001213900-26-068871","cik":"0001839285","ticker":"HCTI","company_name":"Healthcare Triangle, Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"ea0294780-8k_healthcare.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1839285/000121390026068871/ea0294780-8k_healthcare.htm"},"events":[{"id":11119,"run_id":9749,"accession_number":"0001213900-26-068871","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.93,"summary":"Healthcare Triangle completed a private placement of $4.235 million principal amount of convertible notes (gross proceeds ~$3.6 million) and entered into a $50 million equity line of credit with Hudson Global Ventures. Both transactions involve unregistered equity issuances with significant dilution potential: the convertible notes are convertible at 85% of VWAP (floor $0.452/share), and the equity line permits up to $50 million in future share purchases at 94% of market prices, with an additional warrant for 50,000 shares at nominal exercise price.","company_name":"Healthcare Triangle, Inc.","ticker":"HCTI","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7621,"accession_number":"0001213900-26-068871","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Healthcare Triangle completed a private placement of $4.235 million principal amount of convertible notes with gross proceeds of ~$3.6 million, plus entered into a $50 million equity line of credit with Hudson Global Ventures. Both transactions involve unregistered equity issuances with significant dilution potential: the convertible notes are convertible at 85% of VWAP (floor $0.452/share), and the equity line permits up to $50 million in future share purchases at 94% of market prices, with an additional warrant for 50,000 shares at nominal exercise price. These are classic dilutive financing structures typical of small-cap companies in financial stress, materially affecting shareholder equity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T21:01:25.252114+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7622,"accession_number":"0001213900-26-068871","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation related to \"Notes\" by cross-reference to Item 1.01. Without the full Item 1.01 text describing the nature, amount, and terms of the Notes, the specific event type cannot be determined with confidence. This could represent debt issuance, convertible notes (potentially dilutive_issuance), or another financing arrangement. The materiality is clear given the Item 2.03 filing requirement, but the precise classification requires visibility into Item 1.01 details.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T21:01:25.252114+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7623,"accession_number":"0001213900-26-068871","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered sale of convertible notes and warrants with shares of common stock issuable upon conversion and exercise, offered under Section 4(a)(2) and Rule 506(b) exemptions. The issuance of convertible securities and warrants that dilute existing shareholders is a classic dilutive issuance event material to investors assessing ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T21:01:25.252114+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7624,"accession_number":"0001213900-26-068871","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The filing discloses closing of a \"Note Offering\" via press release on June 12, 2026. While the exact terms are not detailed in the Item 7.01 excerpt, a note offering typically involves issuance of debt securities that may be convertible into equity, which would be dilutive to existing shareholders. The company's decision to announce this via Regulation FD disclosure and furnish a press release signals material financing activity that would affect investor assessment of capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T21:01:25.252114+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7621,"accession_number":"0001213900-26-068871","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Healthcare Triangle completed a private placement of $4.235 million principal amount of convertible notes with gross proceeds of ~$3.6 million, plus entered into a $50 million equity line of credit with Hudson Global Ventures. Both transactions involve unregistered equity issuances with significant dilution potential: the convertible notes are convertible at 85% of VWAP (floor $0.452/share), and the equity line permits up to $50 million in future share purchases at 94% of market prices, with an additional warrant for 50,000 shares at nominal exercise price. These are classic dilutive financing structures typical of small-cap companies in financial stress, materially affecting shareholder equity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T21:01:25.252114+00:00","company_name":"Healthcare Triangle, Inc.","ticker":"HCTI","filing_date":"2026-06-15"},{"id":7622,"accession_number":"0001213900-26-068871","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation related to \"Notes\" by cross-reference to Item 1.01. Without the full Item 1.01 text describing the nature, amount, and terms of the Notes, the specific event type cannot be determined with confidence. This could represent debt issuance, convertible notes (potentially dilutive_issuance), or another financing arrangement. The materiality is clear given the Item 2.03 filing requirement, but the precise classification requires visibility into Item 1.01 details.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T21:01:25.252114+00:00","company_name":"Healthcare Triangle, Inc.","ticker":"HCTI","filing_date":"2026-06-15"},{"id":7623,"accession_number":"0001213900-26-068871","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered sale of convertible notes and warrants with shares of common stock issuable upon conversion and exercise, offered under Section 4(a)(2) and Rule 506(b) exemptions. The issuance of convertible securities and warrants that dilute existing shareholders is a classic dilutive issuance event material to investors assessing ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T21:01:25.252114+00:00","company_name":"Healthcare Triangle, Inc.","ticker":"HCTI","filing_date":"2026-06-15"},{"id":7624,"accession_number":"0001213900-26-068871","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The filing discloses closing of a \"Note Offering\" via press release on June 12, 2026. While the exact terms are not detailed in the Item 7.01 excerpt, a note offering typically involves issuance of debt securities that may be convertible into equity, which would be dilutive to existing shareholders. The company's decision to announce this via Regulation FD disclosure and furnish a press release signals material financing activity that would affect investor assessment of capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T21:01:25.252114+00:00","company_name":"Healthcare Triangle, Inc.","ticker":"HCTI","filing_date":"2026-06-15"}]}